Donate

The Nuclear Medicine Department would like to offer a new therapy to their prostate cancer patients.  However, to offer this treatment, refurbishment of the existing patient waiting area and therapy rooms is needed.

Lutetium-177 (177Lu)-PSMA-617 is a new innovative therapy, where a radioactive dose is injected into the patient, targeting the disease and treating it directly, unlike chemotherapy, which treats the body as a whole.

The Nuclear Medicine Department would like to offer this new therapy to their prostate cancer patients.  However, to offer this treatment, refurbishment of the existing patient waiting area and therapy rooms is needed.

We are raising funds to create this space.

This new space will allow the patients to receive their treatment as a ‘day case’, rather than needing to stay in the ward overnight.